NEUROPACE INC (NPCE) Fundamental Analysis & Valuation

NASDAQ:NPCE • US6412881053

14.27 USD
+0.67 (+4.93%)
Last: Mar 6, 2026, 02:59 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This NPCE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NPCE. NPCE was compared to 184 industry peers in the Health Care Equipment & Supplies industry. NPCE may be in some trouble as it scores bad on both profitability and health. NPCE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. NPCE Profitability Analysis

1.1 Basic Checks

  • NPCE had negative earnings in the past year.
  • NPCE had a negative operating cash flow in the past year.
  • NPCE had negative earnings in each of the past 5 years.
  • NPCE had a negative operating cash flow in each of the past 5 years.
NPCE Yearly Net Income VS EBIT VS OCF VS FCFNPCE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • NPCE has a Return On Assets (-22.36%) which is comparable to the rest of the industry.
  • With a Return On Equity value of -129.53%, NPCE is not doing good in the industry: 65.76% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -22.36%
ROE -129.53%
ROIC N/A
ROA(3y)-33.52%
ROA(5y)-34.1%
ROE(3y)-211.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NPCE Yearly ROA, ROE, ROICNPCE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

  • With an excellent Gross Margin value of 76.77%, NPCE belongs to the best of the industry, outperforming 88.04% of the companies in the same industry.
  • In the last couple of years the Gross Margin of NPCE has remained more or less at the same level.
  • NPCE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y0.65%
NPCE Yearly Profit, Operating, Gross MarginsNPCE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. NPCE Health Analysis

2.1 Basic Checks

  • NPCE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for NPCE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NPCE Yearly Shares OutstandingNPCE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
NPCE Yearly Total Debt VS Total AssetsNPCE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -2.96, we must say that NPCE is in the distress zone and has some risk of bankruptcy.
  • NPCE's Altman-Z score of -2.96 is on the low side compared to the rest of the industry. NPCE is outperformed by 64.67% of its industry peers.
  • A Debt/Equity ratio of 3.17 is on the high side and indicates that NPCE has dependencies on debt financing.
  • NPCE has a Debt to Equity ratio of 3.17. This is amonst the worse of the industry: NPCE underperforms 84.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.17
Debt/FCF N/A
Altman-Z -2.96
ROIC/WACCN/A
WACC10.4%
NPCE Yearly LT Debt VS Equity VS FCFNPCE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • NPCE has a Current Ratio of 4.86. This indicates that NPCE is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 4.86, NPCE is in the better half of the industry, outperforming 75.54% of the companies in the same industry.
  • A Quick Ratio of 3.94 indicates that NPCE has no problem at all paying its short term obligations.
  • The Quick ratio of NPCE (3.94) is better than 73.37% of its industry peers.
Industry RankSector Rank
Current Ratio 4.86
Quick Ratio 3.94
NPCE Yearly Current Assets VS Current LiabilitesNPCE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. NPCE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 30.53% over the past year.
EPS 1Y (TTM)30.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%23.87%

3.2 Future

  • NPCE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.65% yearly.
  • The Revenue is expected to grow by 16.68% on average over the next years. This is quite good.
EPS Next Y-16.79%
EPS Next 2Y18.34%
EPS Next 3Y30.38%
EPS Next 5Y20.65%
Revenue Next Year0.28%
Revenue Next 2Y12.17%
Revenue Next 3Y17.02%
Revenue Next 5Y16.68%

3.3 Evolution

NPCE Yearly Revenue VS EstimatesNPCE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
NPCE Yearly EPS VS EstimatesNPCE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. NPCE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NPCE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NPCE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NPCE Price Earnings VS Forward Price EarningsNPCE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NPCE Per share dataNPCE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NPCE's earnings are expected to grow with 30.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.34%
EPS Next 3Y30.38%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NPCE Dividend Analysis

5.1 Amount

  • NPCE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NPCE Fundamentals: All Metrics, Ratios and Statistics

NEUROPACE INC

NASDAQ:NPCE (3/6/2026, 2:59:02 PM)

14.27

+0.67 (+4.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-03
Earnings (Next)05-11
Inst Owners71.36%
Inst Owner Change4.81%
Ins Owners2.5%
Ins Owner Change-0.01%
Market Cap472.05M
Revenue(TTM)N/A
Net Income(TTM)-23.99M
Analysts84.29
Price Target19.89 (39.38%)
Short Float %3.46%
Short Ratio4.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.24%
Min EPS beat(2)-14.56%
Max EPS beat(2)45.05%
EPS beat(4)3
Avg EPS beat(4)16.51%
Min EPS beat(4)-14.56%
Max EPS beat(4)45.05%
EPS beat(8)7
Avg EPS beat(8)17.82%
EPS beat(12)11
Avg EPS beat(12)18.53%
EPS beat(16)12
Avg EPS beat(16)11.45%
Revenue beat(2)1
Avg Revenue beat(2)4.37%
Min Revenue beat(2)-0.11%
Max Revenue beat(2)8.86%
Revenue beat(4)2
Avg Revenue beat(4)2.31%
Min Revenue beat(4)-0.6%
Max Revenue beat(4)8.86%
Revenue beat(8)6
Avg Revenue beat(8)3.06%
Revenue beat(12)10
Avg Revenue beat(12)6.97%
Revenue beat(16)13
Avg Revenue beat(16)5.57%
PT rev (1m)1.3%
PT rev (3m)11.43%
EPS NQ rev (1m)1.85%
EPS NQ rev (3m)17.59%
EPS NY rev (1m)3.68%
EPS NY rev (3m)15.54%
Revenue NQ rev (1m)-0.68%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)0.52%
Revenue NY rev (3m)3.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.98
P/FCF N/A
P/OCF N/A
P/B 25.49
P/tB 25.49
EV/EBITDA N/A
EPS(TTM)-0.66
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS2.87
BVpS0.56
TBVpS0.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -22.36%
ROE -129.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.77%
FCFM N/A
ROA(3y)-33.52%
ROA(5y)-34.1%
ROE(3y)-211.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y0.65%
F-Score5
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 3.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.99%
Cap/Sales 0.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.86
Quick Ratio 3.94
Altman-Z -2.96
F-Score5
WACC10.4%
ROIC/WACCN/A
Cap/Depr(3y)156.88%
Cap/Depr(5y)123.33%
Cap/Sales(3y)0.66%
Cap/Sales(5y)0.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.56%
EPS Next Y-16.79%
EPS Next 2Y18.34%
EPS Next 3Y30.38%
EPS Next 5Y20.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%23.87%
Revenue Next Year0.28%
Revenue Next 2Y12.17%
Revenue Next 3Y17.02%
Revenue Next 5Y16.68%
EBIT growth 1Y21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.1%
EBIT Next 3Y32.1%
EBIT Next 5YN/A
FCF growth 1Y32.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.61%
OCF growth 3YN/A
OCF growth 5YN/A

NEUROPACE INC / NPCE FAQ

Can you provide the ChartMill fundamental rating for NEUROPACE INC?

ChartMill assigns a fundamental rating of 2 / 10 to NPCE.


What is the valuation status of NEUROPACE INC (NPCE) stock?

ChartMill assigns a valuation rating of 1 / 10 to NEUROPACE INC (NPCE). This can be considered as Overvalued.


How profitable is NEUROPACE INC (NPCE) stock?

NEUROPACE INC (NPCE) has a profitability rating of 1 / 10.


What is the expected EPS growth for NEUROPACE INC (NPCE) stock?

The Earnings per Share (EPS) of NEUROPACE INC (NPCE) is expected to decline by -16.79% in the next year.